双重抗血小板联合即刻强化他汀治疗轻型缺血性卒中:随机试验
该多中心随机双盲安慰剂对照2×2析因试验纳入6100例推定动脉粥样硬化性急性轻型缺血性卒中或TIA患者,比较氯吡格雷-阿司匹林与单用阿司匹林、即刻与延迟强化他汀的疗效。主要结果显示氯吡格雷-阿司匹林联合延迟强化他汀较阿司匹林联合延迟强化他汀显著降低90天新发卒中风险(HR 0.69, 95%CI 0.54-0.89),但中重度出血风险低但略有增加。
要点
- 氯吡格雷-阿司匹林联合延迟强化他汀较阿司匹林联合延迟强化他汀显著降低90天新发卒中风险。
- 氯吡格雷-阿司匹林联合即刻强化他汀亦降低新发卒中风险(HR 0.76, 95%CI 0.60-0.97)。
- 联合治疗中重度出血风险低但略有增加,需权衡获益与风险。
核心结论
- 在推定动脉粥样硬化性轻型缺血性卒中或TIA患者中,氯吡格雷-阿司匹林联合延迟强化他汀优于阿司匹林联合延迟强化他汀,可降低90天新发卒中风险。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的2×2析因试验,纳入中国222家医院的6100例患者。
- 患者为症状发作72小时内的急性轻型缺血性卒中或TIA,推定动脉粥样硬化性病因。
- 随机分配至氯吡格雷+阿司匹林或单用阿司匹林,以及即刻或延迟强化他汀治疗,每组1525例。
主要发现
- 90天新发卒中在氯吡格雷-阿司匹林+即刻强化他汀组116例(7.6%),HR 0.76(95%CI 0.60-0.97)。
- 90天新发卒中在氯吡格雷-阿司匹林+延迟强化他汀组106例(7.0%),HR 0.69(95%CI 0.54-0.89)。
- 90天新发卒中在阿司匹林+即刻强化他汀组129例(8.5%),HR 0.85(95%CI 0.67-1.07)。
- 90天新发卒中在阿司匹林+延迟强化他汀组150例(9.9%)。
- 中重度出血在氯吡格雷-阿司匹林+即刻强化他汀组17例(1.1%,p=0.047),在氯吡格雷-阿司匹林+延迟强化他汀组10例(0.7%,p=0.46),在阿司匹林+即刻强化他汀组6例(0.4%,p=0.80),在阿司匹林+延迟强化他汀组7例(0.5%)。
关键数值与推荐
- 主要疗效结局为90天内新发卒中(缺血性或出血性),主要安全结局为中重度出血。
- 氯吡格雷-阿司匹林联合延迟强化他汀较阿司匹林联合延迟强化他汀降低90天新发卒中风险(HR 0.69, 95%CI 0.54-0.89)。
- 氯吡格雷-阿司匹林联合即刻强化他汀较阿司匹林联合延迟强化他汀降低90天新发卒中风险(HR 0.76, 95%CI 0.60-0.97)。
临床怎么用
- 对于推定动脉粥样硬化性轻型缺血性卒中或TIA患者,可考虑氯吡格雷-阿司匹林联合延迟强化他汀以降低90天新发卒中风险。
- 使用联合抗血小板治疗时需评估中重度出血风险,尽管发生率低但较单用阿司匹林有所增加。
局限性
- 研究仅纳入中国患者,结果可能不完全适用于其他人群。
- 中重度出血事件数较少,需更大样本验证安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Previous studies have shown a beneficial effect of clopidogrel-aspirin and intensive statin therapy in acute ischemic stroke; however, the synergistic effect of the 2 treatments is still unclear. The aim of this study was to investigate the effect of combining clopidogrel-aspirin and immediate intensive statin in patients with acute mild ischemic stroke or transient ischemic attack (TIA). METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial with a 2-by-2 factorial design across 222 hospitals in China. Eligible participants were patients with acute mild ischemic stroke or TIA of a presumed atherosclerotic cause within 72 hours of symptom onset. Patients were randomly assigned to receive clopidogrel plus aspirin or aspirin alone and an immediate or delayed intensive statin. The primary efficacy outcome was a new stroke (ischemic or hemorrhagic) within 90 days, and the primary safety outcome was moderate-to-severe bleeding. RESULTS: Between September 17, 2018, and October 15, 2022, 6,100 patients were enrolled (median age, 65 years; 64.2% male), of whom 1,525 each were assigned to the 4 groups. New stroke within 90 days occurred in 116 patients (7.6%) in the clopidogrel-aspirin plus immediate intensive statin group (hazard ratio [HR] 0.76, 95% CI 0.60-0.97), in 106 patients (7.0%) in the clopidogrel-aspirin plus delayed statin group (HR 0.69, 95% Cl 0.54-0.89), and in 129 patients (8.5%) in the aspirin plus immediate statin group (HR 0.85, 95% Cl 0.67 to 1.07), compared with 150 patients (9.9%) in the aspirin plus delayed intensive statin group. Moderate-to-severe bleeding occurred in 17 (1.1%) in the clopidogrel-aspirin plus immediate statin group (p = 0.047), 10 (0.7%) in the clopidogrel-aspirin plus delayed statin group (p = 0.46), and 6 (0.4%) in the aspirin plus immediate statin group (p = 0.80), compared with 7 (0.5%) in the aspirin plus delayed statin group. DISCUSSION: Among patients with mild ischemic stroke or TIA of presumed atherosclerotic cause, the combination of clopidogrel-aspirin and delayed intensive statin was superior to aspirin plus delayed intensive statin in reducing the risk of new stroke, an effect that was mainly driven by clopidogrel-aspirin and not significantly different from that of clopidogrel-aspirin plus immediate statin. The combination treatment had a low but increased risk of moderate-to-severe bleeding. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov identifier: NCT03635749. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with mild ischemic stroke or TIA of presumed atherosclerotic cause, the combination of clopidogrel-aspirin plus delayed intensive statin was superior to aspirin plus delayed intensive statin in reducing the 90-day risk of new stroke.
引用
- Pan Y, Gao Y, Chen W, et al. Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial. Neurology. 2026. PMID: 42348803. doi:10.1212/WNL.0000000000218128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。